Details for Patent: 8,962,829

Which drugs does patent 8,962,829 protect, and when does it expire?

Patent 8,962,829 protects TEMBEXA and is included in one NDA.

This patent has twenty-eight patent family members in fourteen countries.

Summary for Patent: 8,962,829

Patent landscape, scope, and claims:

Title:	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
Abstract:	The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of phosphonate ester compounds.
Inventor(s):	Ware, Jr.; Roy Wendell (Raleigh, NC), Downey; Aaron Leigh (Durham, NC)
Assignee:	Chimerix, Inc. (Durham, NC)
Application Number:	14/512,335
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Process;

Drugs Protected by US Patent 8,962,829

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emergent Biodefense	TEMBEXA	brincidofovir	TABLET;ORAL	214461-001	Jun 4, 2021		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,962,829

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014349103
Australia	2017202386
Australia	2017203315
Brazil	112016010862
Canada	2929593